SREBP2 inhibitor betulin sensitizes hepatocellular carcinoma to lenvatinib by inhibiting the mTOR/IL-1β pathway
Lenvatinib has become the first-line therapy in advanced hepatocellular carcinoma (HCC), but its efficacy is still limited because of the inevitable development of resistance. It has been reported that cellular cholesterol levels are associ...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
China Science Publishing & Media Ltd.
2023-07-01
|
Series: | Acta Biochimica et Biophysica Sinica |
Subjects: | |
Online Access: | https://www.sciengine.com/doi/10.3724/abbs.2023122 |